heya8 Search Results


heya8-mdr cells  (CEM Corporation)
90
CEM Corporation heya8-mdr cells
Heya8 Mdr Cells, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/heya8/pmc05834263-167-5-12?v=CEM+Corporation
Average 90 stars, based on 1 article reviews
heya8-mdr cells - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cell lines heya8  (JCRB Cell Bank)
90
JCRB Cell Bank cell lines heya8
Cell Lines Heya8, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/heya8/pm39700008-233-2-30?v=JCRB+Cell+Bank
Average 90 stars, based on 1 article reviews
cell lines heya8 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
heya8  (Korean Cell Line Bank)
86
Korean Cell Line Bank heya8
Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and <t>HEYA8</t> ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).
Heya8, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/heya8/pmc12897294-145-13-23?v=Korean+Cell+Line+Bank
Average 86 stars, based on 1 article reviews
heya8 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and HEYA8 ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and HEYA8 ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).

Article Snippet: Human ovarian cancer cell line SK-OV3 (high-grade serous ovarian cancer cell line) and HEYA8 (metastatic ovarian cancer cell line) were obtained from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

Techniques: Control

Cell migration, invasion, and wound healing assay to silence of FOXA1 in ovarian cancer cells. ( a ) FOXA1 si decreased the migration ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( b ) FOXA1 si decreased the invasion ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( c ) Representative images of the wound healing assay at 0, 12, 24, 36, and 48 h time points (Left: SK-OV3, Right: HEYA8). ( d ) The quantitative evaluation and statistical analysis of wound area percentage in wound healing assay measured by Image J software. Results are expressed as mean ± SD of five experiments (Left: SK-OV3, Right: HEYA8).

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Cell migration, invasion, and wound healing assay to silence of FOXA1 in ovarian cancer cells. ( a ) FOXA1 si decreased the migration ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( b ) FOXA1 si decreased the invasion ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( c ) Representative images of the wound healing assay at 0, 12, 24, 36, and 48 h time points (Left: SK-OV3, Right: HEYA8). ( d ) The quantitative evaluation and statistical analysis of wound area percentage in wound healing assay measured by Image J software. Results are expressed as mean ± SD of five experiments (Left: SK-OV3, Right: HEYA8).

Article Snippet: Human ovarian cancer cell line SK-OV3 (high-grade serous ovarian cancer cell line) and HEYA8 (metastatic ovarian cancer cell line) were obtained from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

Techniques: Migration, Wound Healing Assay, Software

Comparison of EMT gene expression after treatment with FOXA1 siRNA. ( a ) Changes in EMT gene expression in HEYA8. ( b ) Changes in EMT gene expression in SK-OV3. ( c ) Schematic representation of EMT and MET processes and their key molecular markers.

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Comparison of EMT gene expression after treatment with FOXA1 siRNA. ( a ) Changes in EMT gene expression in HEYA8. ( b ) Changes in EMT gene expression in SK-OV3. ( c ) Schematic representation of EMT and MET processes and their key molecular markers.

Article Snippet: Human ovarian cancer cell line SK-OV3 (high-grade serous ovarian cancer cell line) and HEYA8 (metastatic ovarian cancer cell line) were obtained from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

Techniques: Comparison, Gene Expression

Reduction in chemoresistance following FOXA1 Gene Knockdown. ( a ) Determining IC50 values using carboplatin. ( b ) Atezolizumab cytotoxicity test in SK-OV3 and HEY A8 cells. ( c , d ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without atezolizumab. ( e , f ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without FOXA1 knockdown. ( g , h ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following combined treatment with carboplatin and atezolizumab, with or without FOXA1 knockdown. ( i , j ) Comparison of cell viability in FOXA1-silenced SK-OV3 and HEYA8 cells treated with carboplatin alone or in combination with atezolizumab.

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Reduction in chemoresistance following FOXA1 Gene Knockdown. ( a ) Determining IC50 values using carboplatin. ( b ) Atezolizumab cytotoxicity test in SK-OV3 and HEY A8 cells. ( c , d ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without atezolizumab. ( e , f ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without FOXA1 knockdown. ( g , h ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following combined treatment with carboplatin and atezolizumab, with or without FOXA1 knockdown. ( i , j ) Comparison of cell viability in FOXA1-silenced SK-OV3 and HEYA8 cells treated with carboplatin alone or in combination with atezolizumab.

Article Snippet: Human ovarian cancer cell line SK-OV3 (high-grade serous ovarian cancer cell line) and HEYA8 (metastatic ovarian cancer cell line) were obtained from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

Techniques: Knockdown, Comparison